Genmab A/S (GMAB) Expected to Post Earnings on Thursday

Genmab A/S (NASDAQ:GMAB) is projected to release its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Genmab A/S to post earnings of $0.37 per share and revenue of $1.1110 billion for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 12:00 PM ET.

Genmab A/S Stock Performance

Shares of GMAB opened at $29.02 on Wednesday. The company has a debt-to-equity ratio of 0.87, a current ratio of 2.18 and a quick ratio of 2.17. The firm’s 50 day moving average is $27.11 and its 200-day moving average is $28.04. Genmab A/S has a 12-month low of $21.00 and a 12-month high of $35.43. The stock has a market capitalization of $18.09 billion, a P/E ratio of 21.99, a P/E/G ratio of 1.80 and a beta of 0.83.

Analyst Upgrades and Downgrades

GMAB has been the subject of a number of research reports. Weiss Ratings upgraded shares of Genmab A/S from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, July 28th. New Street Research set a $43.00 price target on Genmab A/S in a report on Wednesday, July 22nd. Truist Financial initiated coverage on Genmab A/S in a research report on Wednesday, May 27th. They set a “buy” rating and a $40.00 price objective for the company. HC Wainwright raised their price objective on Genmab A/S from $38.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, July 2nd. Finally, BNP Paribas Exane upgraded Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Wednesday, April 22nd. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, Genmab A/S presently has a consensus rating of “Moderate Buy” and an average target price of $39.28.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Orbis Allan Gray Ltd lifted its position in shares of Genmab A/S by 30.2% in the 4th quarter. Orbis Allan Gray Ltd now owns 14,418,462 shares of the company’s stock valued at $444,089,000 after acquiring an additional 3,340,456 shares in the last quarter. Paradigm Biocapital Advisors LP grew its position in Genmab A/S by 84.4% during the 4th quarter. Paradigm Biocapital Advisors LP now owns 7,039,834 shares of the company’s stock worth $216,827,000 after purchasing an additional 3,222,983 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its position in Genmab A/S by 5.5% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 3,643,139 shares of the company’s stock worth $111,735,000 after purchasing an additional 188,761 shares in the last quarter. Renaissance Technologies LLC raised its stake in Genmab A/S by 23.8% during the 4th quarter. Renaissance Technologies LLC now owns 3,492,850 shares of the company’s stock valued at $107,580,000 after purchasing an additional 671,307 shares during the period. Finally, Morgan Stanley raised its stake in Genmab A/S by 9.5% during the 4th quarter. Morgan Stanley now owns 1,834,439 shares of the company’s stock valued at $56,501,000 after purchasing an additional 159,865 shares during the period. 7.07% of the stock is owned by hedge funds and other institutional investors.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.